JP2009544754A
(ja)
*
|
2006-07-28 |
2009-12-17 |
アプライド バイオシステムズ, エルエルシー |
ジヌクレオチドmrnaキャップアナログ
|
WO2009058911A2
(en)
*
|
2007-10-31 |
2009-05-07 |
Applied Biosystems Inc. |
Preparation and isolation of 5' capped mrna
|
EP2281579A1
(en)
*
|
2009-08-05 |
2011-02-09 |
BioNTech AG |
Vaccine composition comprising 5'-Cap modified RNA
|
CN101671669B
(zh)
*
|
2009-08-27 |
2012-05-02 |
浙江大学 |
一种肝癌靶向性基因表达元件ae及其应用
|
EP3578205A1
(en)
|
2010-08-06 |
2019-12-11 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
CA2813466A1
(en)
|
2010-10-01 |
2012-04-05 |
Moderna Therapeutics, Inc. |
Modified nucleosides, nucleotides, and nucleic acids that disrupt major groove binding partner interactions
|
EP2691101A2
(en)
|
2011-03-31 |
2014-02-05 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
KR102014061B1
(ko)
|
2011-10-03 |
2019-08-28 |
모더나 세라퓨틱스, 인코포레이티드 |
변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
|
LT2791160T
(lt)
|
2011-12-16 |
2022-06-10 |
Modernatx, Inc. |
Modifikuotos mrnr sudėtys
|
CN108285491B
(zh)
|
2012-02-29 |
2021-08-10 |
桑格摩生物科学股份有限公司 |
治疗亨廷顿氏病的方法和组合物
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
AU2013243947A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
CA2892529C
(en)
|
2012-11-26 |
2023-04-25 |
Moderna Therapeutics, Inc. |
Terminally modified rna
|
JP6491113B2
(ja)
|
2013-02-25 |
2019-03-27 |
サンガモ セラピューティクス, インコーポレイテッド |
ヌクレアーゼ媒介性遺伝子破壊を増強するための方法および組成物
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
MX2016004249A
(es)
|
2013-10-03 |
2016-11-08 |
Moderna Therapeutics Inc |
Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad.
|
BR112016010175A2
(pt)
|
2013-11-11 |
2017-10-03 |
Sangamo Biosciences Inc |
Repressor genético, seus usos, e composição farmacêutica
|
EP3960856A1
(en)
|
2013-11-13 |
2022-03-02 |
Children's Medical Center Corporation |
Nuclease-mediated regulation of gene expression
|
CA3229275A1
(en)
|
2013-12-09 |
2015-06-18 |
Sangamo Biosciences, Inc. |
Methods and compositions for genome engineering
|
AU2014375404C1
(en)
|
2013-12-30 |
2020-11-19 |
CureVac Manufacturing GmbH |
Methods for RNA analysis
|
EP3540060A1
(en)
|
2013-12-30 |
2019-09-18 |
CureVac AG |
Methods for rna analysis
|
LT3102673T
(lt)
|
2014-02-03 |
2020-08-25 |
Sangamo Therapeutics, Inc. |
Beta talasemijos gydymo būdai ir kompozicijos
|
WO2015143046A2
(en)
|
2014-03-18 |
2015-09-24 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of zinc finger protein expression
|
US9522936B2
(en)
|
2014-04-24 |
2016-12-20 |
Sangamo Biosciences, Inc. |
Engineered transcription activator like effector (TALE) proteins
|
WO2015171932A1
(en)
|
2014-05-08 |
2015-11-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating huntington's disease
|
CA2947622A1
(en)
|
2014-05-13 |
2015-11-19 |
Sangamo Biosciences, Inc. |
Genome editing methods and compositions for prevention or treatment of a disease
|
US9970001B2
(en)
|
2014-06-05 |
2018-05-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for nuclease design
|
US10837039B2
(en)
|
2014-06-10 |
2020-11-17 |
Curevac Real Estate Gmbh |
Methods and means for enhancing RNA production
|
WO2016014837A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Gene editing for hiv gene therapy
|
US9616090B2
(en)
|
2014-07-30 |
2017-04-11 |
Sangamo Biosciences, Inc. |
Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
US20180112213A1
(en)
|
2015-03-25 |
2018-04-26 |
Editas Medicine, Inc. |
Crispr/cas-related methods, compositions and components
|
WO2016161446A1
(en)
|
2015-04-03 |
2016-10-06 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of genome editing of b-cells
|
EP3326641B1
(en)
|
2015-04-22 |
2019-06-26 |
CureVac AG |
Rna containing composition for treatment of tumor diseases
|
CA2986310A1
(en)
|
2015-05-11 |
2016-11-17 |
Editas Medicine, Inc. |
Optimized crispr/cas9 systems and methods for gene editing in stem cells
|
WO2016183236A1
(en)
|
2015-05-11 |
2016-11-17 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating hiv infection and aids
|
EP3294866A4
(en)
|
2015-05-12 |
2018-12-05 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
EP3744843A1
(en)
|
2015-05-29 |
2020-12-02 |
CureVac Real Estate GmbH |
A method for producing and purifying rna, comprising at least one step of tangential flow filtration
|
CA2986262A1
(en)
|
2015-06-09 |
2016-12-15 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for improving transplantation
|
US9957501B2
(en)
|
2015-06-18 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
US20190017100A1
(en)
|
2015-07-01 |
2019-01-17 |
Curevac Ag |
Method for analysis of an rna molecule
|
EP3906789B1
(en)
|
2015-09-21 |
2023-11-22 |
TriLink BioTechnologies, LLC |
Initiating capped oligonucleotide primers for synthesizing 5'-capped rnas
|
CA2998500A1
(en)
|
2015-09-23 |
2017-03-30 |
Sangamo Therapeutics, Inc. |
Htt repressors and uses thereof
|
SI3362461T1
(sl)
|
2015-10-16 |
2022-05-31 |
Modernatx, Inc. |
Analogi kape MRNA z modificirano fosfatno povezavo
|
WO2017066797A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Trinucleotide mrna cap analogs
|
CA3001351A1
(en)
|
2015-10-21 |
2017-04-27 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating hepatitis b virus
|
CN109312338B
(zh)
|
2015-10-30 |
2022-09-27 |
爱迪塔斯医药公司 |
治疗单纯疱疹病毒的crispr/cas相关方法及组合物
|
JP6976249B2
(ja)
|
2015-11-23 |
2021-12-08 |
サンガモ セラピューティクス, インコーポレイテッド |
免疫を工学操作するための方法および組成物
|
IL297018A
(en)
|
2015-12-18 |
2022-12-01 |
Sangamo Therapeutics Inc |
Directed cleavage of cell mhc receptor
|
AU2016369490C1
(en)
|
2015-12-18 |
2021-12-23 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the T cell receptor
|
WO2017109161A1
(en)
|
2015-12-23 |
2017-06-29 |
Curevac Ag |
Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
|
PL415967A1
(pl)
*
|
2016-01-29 |
2017-07-31 |
Univ Warszawski |
5'-tiofosforanowe analogi końca 5' mRNA (kapu), sposób ich otrzymywania i zastosowanie
|
WO2017140345A1
(en)
|
2016-02-15 |
2017-08-24 |
Curevac Ag |
Method for analyzing by-products of rna in vitro transcription
|
EP3423595A1
(en)
|
2016-03-03 |
2019-01-09 |
CureVac AG |
Rna analysis by total hydrolysis
|
WO2017162265A1
(en)
|
2016-03-21 |
2017-09-28 |
Biontech Rna Pharmaceuticals Gmbh |
Trans-replicating rna
|
WO2017162266A1
(en)
|
2016-03-21 |
2017-09-28 |
Biontech Rna Pharmaceuticals Gmbh |
Rna replicon for versatile and efficient gene expression
|
WO2017182524A1
(en)
|
2016-04-22 |
2017-10-26 |
Biontech Rna Pharmaceuticals Gmbh |
Methods for providing single-stranded rna
|
EP3452086A1
(en)
|
2016-05-04 |
2019-03-13 |
CureVac AG |
Influenza mrna vaccines
|
US11141474B2
(en)
|
2016-05-04 |
2021-10-12 |
Curevac Ag |
Artificial nucleic acid molecules encoding a norovirus antigen and uses thereof
|
US20180126003A1
(en)
*
|
2016-05-04 |
2018-05-10 |
Curevac Ag |
New targets for rna therapeutics
|
EP3452499A2
(en)
|
2016-05-06 |
2019-03-13 |
Juno Therapeutics, Inc. |
Genetically engineered cells and methods of making the same
|
MA45670A
(fr)
|
2016-07-13 |
2019-05-22 |
Vertex Pharma |
Procédés, compositions et kits pour augmenter l'efficacité d'édition du génome
|
EP3500295A2
(en)
|
2016-08-19 |
2019-06-26 |
CureVac AG |
Rna for cancer therapy
|
KR20220145913A
(ko)
|
2016-08-24 |
2022-10-31 |
상가모 테라퓨틱스, 인코포레이티드 |
가공된 표적 특이적 뉴클레아제
|
HUE056707T2
(hu)
|
2016-08-24 |
2022-03-28 |
Sangamo Therapeutics Inc |
Génexpresszió szabályozása szerkezeti nukleázok alkalmazásával
|
WO2018075736A1
(en)
|
2016-10-20 |
2018-04-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of fabry disease
|
US20200163878A1
(en)
|
2016-10-26 |
2020-05-28 |
Curevac Ag |
Lipid nanoparticle mrna vaccines
|
AU2017347928A1
(en)
|
2016-10-31 |
2019-05-09 |
Sangamo Therapeutics, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
MX2019006426A
(es)
|
2016-12-01 |
2019-08-14 |
Sangamo Therapeutics Inc |
Reguladores de tau, y composiciones y metodos para su administracion.
|
EP3558355A2
(en)
|
2016-12-23 |
2019-10-30 |
CureVac AG |
Henipavirus vaccine
|
US11141476B2
(en)
|
2016-12-23 |
2021-10-12 |
Curevac Ag |
MERS coronavirus vaccine
|
US11920148B2
(en)
|
2017-02-22 |
2024-03-05 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing
|
CN116693411A
(zh)
|
2017-04-28 |
2023-09-05 |
爱康泰生治疗公司 |
用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂
|
WO2018204469A2
(en)
|
2017-05-03 |
2018-11-08 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
BR112019028280A2
(pt)
|
2017-07-04 |
2020-07-14 |
Curevac Ag |
moléculas de ácido nucleico
|
US11602557B2
(en)
|
2017-08-22 |
2023-03-14 |
Cure Vac SE |
Bunyavirales vaccine
|
AU2018333498B2
(en)
|
2017-09-13 |
2023-05-18 |
BioNTech SE |
Method of enhancing RNA expression in a cell
|
US20200277627A1
(en)
|
2017-09-13 |
2020-09-03 |
Biontech Rna Pharmaceuticals Gmbh |
Rna replicon for reprogramming somatic cells
|
CA3074919A1
(en)
|
2017-09-13 |
2019-03-21 |
Biontech Cell & Gene Therapies Gmbh |
Rna replicon for expressing a t cell receptor or an artificial t cell receptor
|
RU2020117848A
(ru)
|
2017-11-08 |
2021-12-08 |
Куревак Аг |
Адаптиция последовательности phk
|
CN111565730A
(zh)
|
2017-11-09 |
2020-08-21 |
桑格摩生物治疗股份有限公司 |
细胞因子诱导型含sh2蛋白(cish)基因的遗传修饰
|
WO2019115635A1
(en)
|
2017-12-13 |
2019-06-20 |
Curevac Ag |
Flavivirus vaccine
|
WO2019122371A1
(en)
|
2017-12-21 |
2019-06-27 |
Curevac Ag |
Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
|
AU2019209292B2
(en)
|
2018-01-17 |
2023-10-05 |
Vertex Pharmaceuticals Incorporated |
Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency
|
BR112020014315A2
(pt)
|
2018-01-17 |
2020-12-08 |
Vertex Pharmaceuticals Incorporated |
Inibidores de dna-pk
|
KR20200109358A
(ko)
|
2018-01-17 |
2020-09-22 |
버텍스 파마슈티칼스 인코포레이티드 |
Dna-pk 억제제
|
JP7416705B2
(ja)
*
|
2018-03-15 |
2024-01-17 |
バイオエヌテック エスエー |
5’キャップトリヌクレオチドまたはより高級のオリゴヌクレオチド化合物、ならびにrnaの安定化、タンパク質の発現および治療法におけるそれらの使用
|
WO2019193183A2
(en)
|
2018-04-05 |
2019-10-10 |
Curevac Ag |
Novel yellow fever nucleic acid molecules for vaccination
|
CA3091558A1
(en)
|
2018-04-17 |
2019-10-24 |
Curevac Ag |
Novel rsv rna molecules and compositions for vaccination
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
EP3813874A1
(en)
|
2018-06-27 |
2021-05-05 |
CureVac AG |
Novel lassa virus rna molecules and compositions for vaccination
|
US20210317430A1
(en)
|
2018-09-18 |
2021-10-14 |
Sangamo Therapeutics, Inc. |
Programmed cell death 1 (pd1) specific nucleases
|
BR112021009422A2
(pt)
|
2018-12-21 |
2021-10-26 |
Curevac Ag |
Rna para vacinas contra malária
|
SG11202106666UA
(en)
|
2018-12-21 |
2021-07-29 |
Curevac Ag |
Methods for rna analysis
|
US11453639B2
(en)
|
2019-01-11 |
2022-09-27 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
CN115120716A
(zh)
|
2019-01-14 |
2022-09-30 |
健泰科生物技术公司 |
用pd-1轴结合拮抗剂和rna疫苗治疗癌症的方法
|
CA3125511A1
(en)
|
2019-02-08 |
2020-08-13 |
Curevac Ag |
Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
|
CA3137368A1
(en)
|
2019-04-23 |
2020-10-29 |
Sangamo Therapeutics, Inc. |
Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof
|
WO2020254535A1
(en)
|
2019-06-18 |
2020-12-24 |
Curevac Ag |
Rotavirus mrna vaccine
|
US20220296628A1
(en)
|
2019-08-14 |
2022-09-22 |
Curevac Ag |
Rna combinations and compositions with decreased immunostimulatory properties
|
US20230090515A1
(en)
|
2019-12-20 |
2023-03-23 |
Curevac Ag |
Lipid nanoparticles for delivery of nucleic acids
|
TW202142257A
(zh)
|
2020-01-31 |
2021-11-16 |
美商建南德克公司 |
用pd-1軸結合拮抗劑及rna疫苗誘導新抗原決定基特異性t細胞之方法
|
JP2023513502A
(ja)
|
2020-02-04 |
2023-03-31 |
キュアバック エスイー |
コロナウイルスワクチン
|
US11576966B2
(en)
|
2020-02-04 |
2023-02-14 |
CureVac SE |
Coronavirus vaccine
|
JP2021185136A
(ja)
*
|
2020-04-22 |
2021-12-09 |
ビオエンテッヒ・アールエヌエイ・ファーマシューティカルズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
コロナウイルスワクチン
|
MX2022015132A
(es)
|
2020-05-29 |
2023-03-08 |
CureVac SE |
Vacunas combinadas a base de acidos nucleicos.
|
US20230265454A1
(en)
|
2020-06-04 |
2023-08-24 |
BioNTech SE |
RNA Replicon for Versatile and Efficient Gene Expression
|
WO2022016070A1
(en)
|
2020-07-16 |
2022-01-20 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|
CA3170741A1
(en)
|
2020-07-31 |
2022-02-03 |
Curevac Ag |
Nucleic acid encoded antibody mixtures
|
CN113201566A
(zh)
*
|
2020-08-20 |
2021-08-03 |
深圳市瑞吉生物科技有限公司 |
一种Cap2结构5′帽子类似物及其制备方法和应用
|
WO2022046760A2
(en)
|
2020-08-25 |
2022-03-03 |
Kite Pharma, Inc. |
T cells with improved functionality
|
US20240066114A1
(en)
|
2020-08-31 |
2024-02-29 |
CureVac SE |
Multivalent nucleic acid based coronavirus vaccines
|
KR20230066395A
(ko)
|
2020-09-08 |
2023-05-15 |
제넨테크, 인크. |
연동 펌프 및 댐프너를 사용하여 약학적 조성물을 생성하기 위한 시스템 및 방법
|
AU2021395736A1
(en)
|
2020-12-09 |
2023-07-27 |
BioNTech SE |
Rna manufacturing
|
WO2022137133A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Rna vaccine against sars-cov-2 variants
|
WO2022135993A2
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
MX2023007574A
(es)
|
2020-12-22 |
2023-09-29 |
CureVac SE |
"vacuna de arn contra variantes de sars-cov-2.
|
WO2022162027A2
(en)
|
2021-01-27 |
2022-08-04 |
Curevac Ag |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
EP4313152A1
(en)
|
2021-03-26 |
2024-02-07 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic compositions
|
EP4312988A2
(en)
|
2021-03-31 |
2024-02-07 |
CureVac SE |
Syringes containing pharmaceutical compositions comprising rna
|
EP4334446A1
(en)
|
2021-05-03 |
2024-03-13 |
CureVac SE |
Improved nucleic acid sequence for cell type specific expression
|
IL308192A
(en)
|
2021-05-04 |
2024-01-01 |
BioNTech SE |
Immunogen selection
|
CA3223943A1
(en)
|
2021-07-29 |
2023-02-02 |
Ugur Sahin |
Compositions and methods for treatment of melanoma
|
CA3171750A1
(en)
|
2021-07-30 |
2023-02-02 |
Tim SONNTAG |
Mrnas for treatment or prophylaxis of liver diseases
|
AU2022336664A1
(en)
|
2021-09-03 |
2024-01-18 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
|
IL309505A
(en)
|
2021-09-03 |
2024-02-01 |
CureVac SE |
Lipid nanoparticles for nucleic acid delivery
|
CN113957108A
(zh)
*
|
2021-09-09 |
2022-01-21 |
上海兆维科技发展有限公司 |
一种加帽rna的合成方法以及加帽rna转录反应液
|
AU2022369342A1
(en)
|
2021-10-18 |
2024-03-14 |
BioNTech SE |
Modified replicable rna and related compositions and their use
|
CA3234214A1
(en)
|
2021-10-18 |
2023-04-27 |
BioNTech SE |
Methods for determining mutations for increasing modified replicable rna function and related compositions and their use
|
WO2023138786A1
(en)
|
2022-01-21 |
2023-07-27 |
BioNTech SE |
Analysis of rna molecules using catalytic nucleic acids
|
WO2023144330A1
(en)
|
2022-01-28 |
2023-08-03 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
WO2023166425A1
(en)
|
2022-03-01 |
2023-09-07 |
Crispr Therapeutics Ag |
Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
|
US20230293646A1
(en)
|
2022-03-21 |
2023-09-21 |
Crispr Therapeutics Ag |
Methods and compositions for treating lipoprotein-related diseases
|
WO2023213378A1
(en)
|
2022-05-02 |
2023-11-09 |
BioNTech SE |
Replicon compositions and methods of using same for the treatment of diseases
|
WO2023227608A1
(en)
|
2022-05-25 |
2023-11-30 |
Glaxosmithkline Biologicals Sa |
Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
|
WO2023237726A1
(en)
|
2022-06-10 |
2023-12-14 |
Pantarhei Oncology B.V. |
An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer
|
US11878055B1
(en)
|
2022-06-26 |
2024-01-23 |
BioNTech SE |
Coronavirus vaccine
|
CN114941018B
(zh)
*
|
2022-06-28 |
2023-09-22 |
翌圣生物科技(上海)股份有限公司 |
cap1帽类似物的合成方法
|
WO2024017479A1
(en)
|
2022-07-21 |
2024-01-25 |
BioNTech SE |
Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production
|
WO2024056856A1
(en)
|
2022-09-15 |
2024-03-21 |
BioNTech SE |
Systems and compositions comprising trans-amplifying rna vectors with mirna
|
WO2024068545A1
(en)
|
2022-09-26 |
2024-04-04 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
DE202023106198U1
(de)
|
2022-10-28 |
2024-03-21 |
CureVac SE |
Impfstoff auf Nukleinsäurebasis
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|